Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia

Xerostomia Clinical Trial

Official title:

UW23129: A Phase I Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06392711
• Other study ID #: 2024-0386
• Secondary ID: A534290SMPH/MEDI
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: May 2024
• Est. completion date: November 2028

Study information

• Verified date: April 2024
• Source: University of Wisconsin, Madison
• Contact: Cancer Connect
• Phone: 800-622-8922
• Email: clinicaltrials[@]cancer.wisc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the safety and tolerability of injecting certain cells that you produce in your bone marrow called mesenchymal stromal cells (MSCs) into your salivary glands. The main question it aims to answer is whether injection of MSCs into your salivary glands results in any improvement in dry mouth. Participants will: - have bone marrow collected using a needle - undergo a salivary gland ultrasound - complete questionnaires - receive an injection of the bone marrow cells into a salivary gland

Description:

This single-center phase I dose-escalation with expansion cohort, open label, non-randomized, non-placebo controlled, single group assignment study will assess the safety and tolerability of mesenchymal stromal cells (MSCs) for treatment of xerostomia, focusing on xerostomia with inflammatory etiology (e.g., Sjögren's disease [SjD], graft-versus-host disease [GVHD]). An initial cohort of subjects (n=6) will receive a unilateral injection of MSCs at dose level 0. If unilateral treatment is tolerated, a dose escalation cohort (n=8-18) will receive bilateral injection of MSCs. Dose escalation will proceed using a standard 3+3 design and once the recommended phase II dose (RP2D) is defined, 12 additional patients will be accrued to the expansion phase. Following the completion of screening/baseline procedures, eligible participants will undergo bone marrow aspiration in order to obtain MSCs. The MSC investigational product will be injected into one or both submandibular glands under local anesthesia at the interventional visit.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 36
• Est. completion date: November 2028
• Est. primary completion date: November 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Xerostomia, defined as an unstimulated salivary flow of less than or equal to 0.5 mL in 5 minutes
• Xerostomia not resulting from radiotherapy (called "medical" xerostomia in this protocol, for example, resulting from Sjögren's Disease or Graft versus Host Disease)
• = 18 years of age, = 90 years of age
• Karnofsky performance status = 70, patient eligible for bone marrow aspirate with wakeful anesthesia
• Willing and able to give informed consent
• Radiographically confirmed bilateral submandibular glands
• If female of childbearing potential, negative pregnancy test
• Males and females of childbearing potential willing to use acceptable contraception
• Laboratory Values (within 42 calendar days of enrollment):
• Hgb = 9 g/dL (5.58 mmol/L)
• Platelets = 100,000/µL
• ANC = 1000/µL
• Lymphocytes = 800/µL
• PT/INR and PTT within normal limits based on age/sex

Exclusion Criteria:

• Patients with one submandibular gland
• Sialolithiasis
• Poorly-controlled diabetes mellitus (HBA1c = 7%)
• Patients who initiated any diuretic therapy before developing dry mouth symptoms or ESRD
• Untreated oral candidiasis based on physical exam at enrollment
• Malignancy within the last 2 years (except adequately treated stage I lung cancer, low risk prostate cancer that has been treated or is undergoing active surveillance, adequately treated non-melanoma skin cancer, adequately treated DCIS, or adequately treated stage I cervical cancer)
• For patients on immunosuppressive therapy, must be on stable dose of immunosuppressive therapy for at least 2 months, allowing for dose adjustments for blood levels of drugs
• Transfusion dependency
• Life expectancy = 6 months as determined by the investigator
• Use of investigational drugs, biologics, or devices within 30 calendar days prior to enrollment
• Pregnant or lactating women or those who plan to become pregnant during the study
• Not suitable for study participation due to other reasons at discretion of investigators.
• Enrollment in another clinical study possibly interfering with the endpoints of this study

Related Conditions & MeSH terms

• Graft vs Host Disease
• Graft-versus-host-disease
• Sjogren's Disease
• Sjogren's Syndrome
• Xerostomia

Intervention

Biological:
• Mesenchymal Stromal Cells (MSC) Dose Level 0
10 (8-12) x 10^6 MSCs
• Mesenchymal Stromal Cells (MSC) Dose Level 1
20 (16-24) x 10^6

Locations

Country	Name	City	State
United States	University of Wisconsin	Madison	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of participants experiencing DLT of submandibular pain	Recommended phase II dose (RP2D) will be determined by the proportion of subjects experiencing the dose-limiting toxicity (DLT) of submandibular pain > 5 on a standard 10-point pain scale of 0-10 at 1-month after MSC injection	1 month post-injection
Primary	Proportion of participants experiencing DLT as serious adverse events (AEs)	RP2D will be determined by the proportion of subjects experiencing the dose-limiting toxicity (DLT) of any serious AE within one-month post-injection	1 month post-injection
Primary	Proportion of participants experiencing DLT as pre-specified toxicities	RP2D will be determined by the proportion of subjects experiencing the dose-limiting toxicity (DLT) of any selected toxicity that is specified in the protocol within one-month post-injection	1 month post-injection
Secondary	Change in xerostomia scores	Xerostomia will be assessed by quality of life xerostomia (XeQoL) scores. XeQoL is a 15-item questionnaire, where items 1-14 are scored as: 0=not at all; 1=a little; 2=somewhat; 3=quite a bit; 4=very much. Item 15 is scored as: 0=delighted; 1=mostly satisfied; 2=mixed: equally satisfied/dissatisfied; 3= mostly dissatisfied; 4=terrible. Lower scores indicate less impact of mouth/throat dryness on QoL, and higher scores indicate great impact on QoL.	Baseline to 24 months
Secondary	Change in salivary function-rate of salivary production	Salivary function determined by measurement of salivary production (g/5 minutes); Unstimulated saliva production will be measured by participants allowing saliva to pool in the mouth over a 5 minute period, then gently guiding saliva into a saliva collection aid; Simulated saliva production will be measured by participants chewing inert gum base to the pace of a metronome (70 beats/minute) while expectorating saliva into a saliva collection aid for 5 minutes. Cryovials containing saliva will be weighed before and after saliva collection and the difference in weight (g) will represent the amount of saliva produced in 5 minutes for each condition.	Baseline, 1 month, 3 moths, 6 months, 12 months, and 24 months
Secondary	Change in salivary function-saliva composition	Salivary function determined by compositional analysis of saliva sample - amylase (mU/mL). Low in disease, hypothesized to increase with intervention.	Baseline, 1 month, 3 moths, 6 months, 12 months, and 24 months
Secondary	Change in salivary function-saliva composition	Salivary function determined by compositional analysis of saliva sample - mucins (MUC5B in mU/mL) assessed using ELISA. Low in disease, hypothesized to increase with intervention.	Baseline, 1 month, 3 moths, 6 months, 12 months, and 24 months
Secondary	Change in salivary function-saliva composition	Salivary function determined by compositional analysis of saliva sample; pH assessed using pH meter. Low in disease, hypothesized to increase with intervention.	Baseline, 1 month, 3 moths, 6 months, 12 months, and 24 months
Secondary	Change in salivary function-saliva composition	Salivary function determined by compositional analysis of saliva sample - total protein (mg/mL). High levels in disease, hypothesized to decrease with intervention.	Baseline, 1 month, 3 moths, 6 months, 12 months, and 24 months